Since established in 2019，Juncell Therapeutics stick to our mission of “rebuild cells, rescue lives” and the vision of “create miracles with tehnology”. We pride ourselves in the values of “focus, innovation, inclusiveness, sharing”, attained several milestones during the company development。
2019
Jun Company establishment
2020
Feb Receiving Pre-A funding at a level of tens of millions RMB
Jun Inauguration of the R&D laboratory and office
Dec Operating the GMP workshops
2021
Jan Enrolling the first patient in the IIT of GC101
Feb Receiving Series A funding at a level of nearly 100 million RMB
Jul Achieving the first CR in the IIT of GC101
Aug Establishing the Viable Cell Bank
Sep Receiving Series A+ funding at a level of tens of millions RMB
Sep Submitting pre-IND meeting application for GC101
Dec Receiving Series A++ funding at a level of nearly 100 million RMB
Dec Granted the National High-Tech Enterprise
2022
Jan Submitting the IND application dossier of GC101 to CDE
Feb CDE accepts the IND application for GC101
Apr IND application for GC101 approved by NMPA
Aug Initiating the Phase I clinical trial of GC101
2023
Feb Winning the highest award in the National Disruptive Technology Innovation Competition sponsored by the Ministry of Science and Technology
Mar Granted the title of Shanghai Specialized and Innovative Enterprises
Jun Enrolling the first patient in the IIT of GC203
Aug Achieving the first PR in the IIT of GC203
2024
Jan Receiving Series B1 funding at a level of nearly 100 millions RMB
Feb CDE accepts the IND application for GC203
Apr IND application for GC203 approved by NMPA
May Initiating the Phase I clinical trial of GC203
Jun Receiving Series B2 funding at a level of nearly 300 millions RMB
